)
)
)
Neovia Oncology, LLC
- US-based clinical stage (Phase II ready) oncology drug development company.
- Accelerated drug development pathway for multiple drug-resistant tumors - 4th line therapy for metastatic colotectal cancer (mCRC).
- ORR in Phase I trial is 22%, with TGI of 62%
- No drug related serious adverse evets (SAEs) in Phase I trial
- Phase Ib/II scheduled to start in Q4 of 2026
- Indications: Multiple drug-resistant solid tumors; metastatic Colorectal cancer (mCRC); SCLC (Small cell lung cancer) without targets; NSCLC (Non small cell lung cancer); Ovarian Cancer
- A novel, patented drug-to-drug conjugate of Topoisomerase I and II dual inhibitors.
- Favorable safety and efficacy in patients with solid tumor who were resistant to previous chemotherapy, radiation therapy and immunotherapy.
Address
Newport BeachCalifornia
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)